doxycycline reference
Reference image
(doxycycline · DailyMed)
Registered Malawi · PMRA

LENTENCLIN 100MG CAPSULE

DOXYCYCLINE

PMPB/PL174/13 CAPSULE alimentary tract and metabolism INN generic

What it does

Doxycycline is an antibiotic used to treat various infections.

Commonly used for: bacterial infections, acne, respiratory infections, malaria prevention

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
PMPB/PL174/13
Registration date
22/02/2002
Expiry date
30/06/2015
Status
Registered
Active ingredient
DOXYCYCLINE
Dosage form
CAPSULE
Strength
-
Pack size
-
Therapeutic class
-
ATC class (WHO)
A01AB - Antiinfectives and antiseptics for local oral treatment
RxNorm RxCUI
3640
Manufacturer / MAH
-
Applicant / LTR
-
Country of origin
-

Source: Pharmacy and Medicines Regulatory Authority · fetched 2026-04-21 17:37:38 · updated 2026-09-15 04:32:43

Drug Interactions

11
Check interactions

Pharmacodynamic Warnings

Doxycycline appears in TABLE 1: Drugs that cause hepatotoxicity

Severe (1)

Tetracyclines - decreases absorption

Strontium is predicted to decrease the absorption of tetracyclines. Avoid. Theoretical Sucralfate

Severe Theoretical

Moderate (5)

Doxycycline - decreases concentration

Fosphenytoin is predicted to decrease the concentration of tetracyclines (doxycycline). Adjust dose.

Moderate Theoretical

Doxycycline - decreases exposure

Rifampicin modestly decreases the exposure to tetracyclines (doxycycline). Adjust dose.

Moderate Study

Lithium - increases risk of lithium toxicity

Tetracyclines are predicted to increase the risk of lithium toxicity when given with lithium. Avoid or adjust dose.

Moderate Anecdotal

Tetracyclines - decreases concentration

Fosphenytoin is predicted to decrease the concentration of tetracyclines (doxycycline). Adjust dose.

Moderate Theoretical

Tetracyclines - decreases exposure

Rifampicin modestly decreases the exposure to tetracyclines (doxycycline). Adjust dose.

Moderate Study

Unknown (5)

Ciclosporin - increases concentration

Doxycyclineispredictedtoincreasetheconcentrationof ciclosporin.rTheoretical

Unknown Theoretical

Tetracyclines - decreases exposure

Mitotane is predicted to decrease the exposure to tetracyclines (eravacycline). Adjust eravacycline dose, p. 625.

Unknown Study

Tetracyclines - decreases exposure

Rifampicin is predicted to decrease the exposure to tetracyclines (eravacycline). Adjust eravacycline dose, p. 625.

Unknown Study

Tetracyclines - decreases exposure

St John's wort is predicted to decrease the exposure to tetracyclines (eravacycline). Adjust eravacycline dose, p. 625.

Unknown Theoretical

Tetracyclines - decreases absorption

Oralzincispredictedtodecreasetheabsorptionof tetracyclines.Separateadministrationby2to3hours. oTheoretical https://www.facebook.c (Books-Courses-Medic

Unknown Theoretical

Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: class

Disclaimer: This information is sourced from Pharmacy and Medicines Regulatory Authority (Malawi). Always consult a qualified healthcare professional before using any medication.

About this medicine

Doxycycline is an antibiotic used to treat various infections.

What it treats

  • bacterial infections
  • acne
  • respiratory infections
  • malaria prevention

How it works

It works by stopping the growth of bacteria.

Who it's for

It is for adults and children who need treatment for bacterial infections.

Drug class

Tetracyclines

Cautions

  • • Be cautious if taking other medications that can harm the liver.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: Doxycycline

BNF-referenced

Doxycycline is a broad-spectrum tetracycline antibiotic effective against a variety of bacterial infections. It acts by inhibiting protein synthesis in susceptible bacteria, thereby halting their growth and replication. It is commonly used for treating infections such as chlamydia, rickettsia, and mycoplasma, and is also indicated for acne and certain periodontal diseases.

Indications

  • Bacterial infections
  • Acne
  • Destructive (refractory) periodontal disease
  • Exacerbations of chronic bronchitis
  • Leptospirosis
  • Chlamydia infections
  • Rickettsial infections
  • Mycoplasma infections
  • Acute necrotising ulcerative gingivitis

Dosage

Children: For children aged 12–17 years, initially 200 mg daily in 1–2 divided doses for the

Adults: Initially 200 mg daily in 1–2 divided doses for the first day, then maintenance 100 mg daily.

Mechanism of action

Doxycycline exerts its antibacterial effects by binding to the 30S ribosomal subunit of bacterial ribosomes, inhibiting the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This inhibition of protein synthesis is crucial for bacterial growth and is the primary mechanism by which doxycycline exhibits its antimicrobial activity. It also impacts cellular metabolism and has been associated with non-genotoxic carcinogenic effects.

Pharmacodynamics

Doxycycline has a broad spectrum of activity against Gram-positive, Gram-negative bacteria, and some protozoa. Its bacteriostatic action is particularly effective against certain resistant strains, including MRSA. The drug's efficacy may vary based on the sensitivity of the bacteria, and resistance can develop through various mechanisms, such as efflux pumps and ribosomal protection.

Pharmacokinetics

Doxycycline is well absorbed from the gastrointestinal tract, with peak plasma concentrations typically reached within 2 hours after oral administration. It has a high volume of distribution and is approximately 90% protein-bound. The drug is metabolized in the liver and excreted primarily in feces, with a smaller fraction eliminated in urine. The half-life of doxycycline is approximately 18 to 22 hours, allowing for once or twice daily dosing in most cases.

Contra-indications

  • Pregnancy
  • Breastfeeding
  • Hypersensitivity to doxycycline or other tetracyclines
  • Myasthenia gravis
  • Severe hepatic impairment

Adverse effects

  • Photosensitivity
  • Dizziness
  • Headache
  • Nausea
  • Vomiting
  • Diarrhoea
  • Angioedema
  • Skin reactions
  • Pseudomembranous enterocolitis
  • Tooth discolouration
  • Intracranial hypertension
  • Thrombocytopenia
  • Stevens-Johnson syndrome
  • Pancreatitis

Interactions

  • Fosphenytoin (decreases concentration)
  • Rifampicin (decreases exposure)
  • Ciclosporin (unknown effect on concentration)
  • Antacids containing aluminium or magnesium (reduce absorption)
  • Iron supplements (reduce absorption)
  • Warfarin (may enhance anticoagulant effect)

Precautions

  • Use with caution in renal impairment
  • May cause increased intracranial pressure
  • Risk of superinfection (e.g., fungal infections)
  • Avoid exposure to sunlight or sun lamps
  • Monitor liver function in patients receiving prolonged therapy

Pregnancy

Should not be given to pregnant women; effects on skeletal development have been documented in the first trimester in animal studies. Administration during the second or third trimester may cause discoloration of the child's teeth, and maternal hepatotoxicity has been reported with large parenteral doses.

Breast-feeding

Should not be given to women who are breastfeeding; absorption may lead to discoloration of teeth in the infant.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

  • Tablets
  • Capsules
  • Oral suspension
  • Oral solution
BNF 85 (British National Formulary) p.643 BNF 85 (British National Formulary) p.1355 BNF for Children 2019-2020 p.386 BNF for Children 2019-2020 p.755 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: Doxycycline

PubChem CID 54671203

Molecular formula: C22H24N2O8

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.